Therefore, we conducted a systematic review and meta-analysis to evaluate the benefit of adding immunotherapy to neoadjuvant chemotherapy in patients with localized NSCLC and conducted subgroup analyses according to clinically relevant parameters, including tumor stage, histology, smoking status, tumor PD-L1 expression, and chemotherapy partner. This evidence concerns the gene CD274 and neoplasm.